News
Public · Published
Axsome Therapeutics Q3 revenue rises on Auvelity and Sunosi
Axsome Therapeutics reported that third-quarter net product revenue rose 52% year over year, driven by Auvelity and Sunosi sales and milestone payments, with increased Symbravo prescriptions also contributing. Its net loss narrowed sharply from the prior year, and it began a Phase 3 trial of AXS-05 for smoking cessation.
Published:
Updated:
What happened
Axsome Therapeutics reported that third-quarter net product revenue rose 52% year over year, driven by Auvelity and Sunosi sales and milestone payments, with increased Symbravo prescriptions also contributing. Its net loss narrowed sharply from the prior year, and it began a Phase 3 trial of AXS-05 for smoking cessation.
Confirmed
Global impact / market context
Revenue growth tied to product demand and milestone payments suggests several sources supported the quarter, while a smaller net loss may reduce the gap between sales and costs. The smoking-cessation trial adds a potential future development, but the article provides no results or launch timing.
Analyst inference
Axsome expects its current cash to fund operations until it reaches cash flow positivity, meaning cash coming in from operations covers cash going out. It also expects continued Auvelity demand and patient starts, alongside clinical results and regulatory milestones through 2027.
Confirmed
What to watch
- Track whether Auvelity demand, new patient starts, Sunosi sales and Symbravo prescriptions continue to support product revenue in coming quarters. Analyst inference
- Watch for updates from the Phase 3 AXS-05 smoking-cessation trial; the article reports that the trial began but gives no results or schedule. Confirmed
- Follow clinical trial results and regulatory milestones expected through 2027, since outcomes could influence future product prospects and spending needs. Confirmed
Evidence
- Original source link unavailable